Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Trial Profile

A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 06 Jul 2023 Primary endpoint (PFS Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 Positive (TPS 1%) Tumors (All Participants) [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ]) has not been met according to Results published in the International Journal of Cancer.
    • 06 Jul 2023 Primary endpoint (Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive (TPS 50%) Tumors [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ]) has not been met according to Results published in the International Journal of Cancer.
    • 06 Jul 2023 Primary endpoint (OS in Participants With PD-L1 Positive (TPS 1%) Tumors (All Participants) [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ] has not been met according to Results published in the International Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top